

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

FIG. 1A

Cell-Specific Adenovirus





FIG. 1B



Taxol (0.625 nM) + CV787 (MOI=0.01)




FIG. 3

FIG. 3 shows the effect of Taxotere (3.12 nM) + CV787 (moi=0.01) on cell viability over 10 days.

Taxotere(3.12 nM) +
CV787(moi=0.01)




FIG. 4

CV787 (moi=0.01) + Taxotere (3.12 nM)

CV787(moi=0.01) +
Taxotere(3.12 nM)






FIG. 5

Mitoxantrone (100 nM) + CV787 (moi=0.1)



Etoposide (500 ng/ml) + CV787 (moi=0.01)



CV787 (moi=0.01) + Doxorubicin (50 ng/ml)






FIG. 8


Cisplatin (8.25 μ M) + CV787 (moi=0.1)



5-Fluorouracil (35 μ M) + CV787 (moi=0.01)



CV787 (moi=0.01) + ¹³⁷Cs (2 Gy)



Virus Yield (LNCaP)





FIG. 12

Virus Yield



Taxol Does not Alter CV787's Specificity





FIG. 14

Specificity of CV787 + Mitoxantrone



CV787 + MTX □ CV787(moi:0.1) ▨ MTX (100nM)

10ng/ml Doxorubicin first,
then 0.01 MOI CV790






FIG. 17


0.01 MOI CV790 and 10ng/ml Doxorubicin together




CV790 0.1 moi/Cisplatin 1ug/ml



CV790 0.1moi/Taxol 0.5ng/ml



CV790 0.1moi/5-FU 10ng/ml








FIG. 22

CV790 0.1moi/Mitomycin C 10ng/ml




Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




—◆— Control —△— CV787, 10⁷p/mm³ —●— Taxol, 15 mg/kg —■— CV787/Taxol

FIG. 24

Tumor Volume of LNCaP Xenograft



Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol



Tumor Volume of LNCaP Xenograft Treated with CV787 and Mitoxantrone






FIG. 27

Tumor Volume of LNCaP Xenografts Treated with CV787 and Estramustine



LNCaP Xenograft Treated with CV787 and Docetaxel



LNCaP Xenograft Treated with CV787 and Docetaxel






FIG. 30

Tumor Volume of Hep3B Treated with CV790 and Doxorubicin




Tumor Volume of Hep3B Xenograft Treated with CV890 and Doxorubicin



Cell Viability


Radiation (6Gy) + CV787(moi=0.1)



- ◇— No treatment
- Radiation
- CV787
- Radiation+CV787

Cell Viability

CV787(moi=0.1) + Radiation (6Gy)



Virus Yield

CV787(moi=0.1) + Radiation (6Gy)




FIG. 35

Virus Yield

Radiation (6Gy) + CV787(moi=0.1)





FIG. 36

Dose Response
LNCaP Treated with CV787 (0.01), then Radiation








FIG. 39



Virus Yield of CV884



Structure of CV876, CV882 and CV884

